Acelity Acquires Crawford Healthcare to Create the World’s Most Expansive Wound Care Portfolio

Acelity Acquires Crawford Healthcare to Create the World’s Most Expansive Wound Care Portfolio

Download Press Release PDF 

Transaction adds complementary key product platforms, significant commercial scale and R&D expertise to Acelity

SAN ANTONIO, USA, and KNUTSFORD, UK, June 8, 2018 – Acelity L.P. Inc., the world’s largest wound care company, and Crawford Healthcare, a rapidly growing UK-based advanced wound care and dermatology company, today announced an agreement for Acelity to acquire Crawford and all of its assets. Terms of the agreement were not disclosed.

With the acquisition of Crawford, Acelity expands its portfolio of advanced wound dressings (AWD), further strengthening its position as the global leader in advanced wound healing.

Crawford Healthcare is a recognized leader in developing and commercializing innovative treatments for the care and repair of skin. Crawford’s wound dressing portfolio includes the market-leading superabsorbent KerraMax Care® range and KerraFoam and KerraCel in the foam and antimicrobial gelling fiber AWD categories, respectively.

Crawford’s advanced wound dressing lines complement Acelity’s existing AWD portfolio, which includes the market-leading collagen dressing PROMOGRAN PRISMA™ Matrix, as well as the TIELLE™ Dressing Family and ADAPTIC™ Dressings. This expanded line of advanced wound dressings combined with Acelity’s industry-leading negative pressure wound therapy platforms forms the world’s most expansive wound care portfolio. In addition to its commercial products, Acelity will acquire Crawford’s innovative R&D capabilities and manufacturing operations based in Cheshire, UK.

“Crawford’s talented team, highly complementary line of advanced wound dressings, and track record of patient-focused innovation make them a terrific partner to accelerate our global growth,” said R. Andrew Eckert, President and CEO of Acelity. “This transaction solidifies our ability to offer the most comprehensive line of wound care solutions and will enable us to create and consolidate leading positions in high-growth market segments; expand and strengthen our customer relationships; and enhance our innovation expertise for the benefit of clinicians and patients around the world.”

Richard Anderson, chief executive of Crawford Healthcare, said: “The rapid growth of the business has been possible due to our focused investment in innovative products which are clinically proven to improve patient outcomes. Becoming part of the world’s largest wound care company will provide us with the scale to optimize our potential within the US, the largest global market and the ability to further access and grow in other international markets with our best-in-class advanced wound care products.”

Richard Anderson will continue to lead the Crawford organization and its products will remain fully available to clinicians and customers as the two companies work together to form integration plans for the remainder of the year.

About Acelity

Acelity L.P. Inc. is a global advanced wound care company committed to developing innovative healing solutions for customers and patients across the care continuum. Its subsidiary, KCI, is the most trusted brand in advanced wound care. The unsurpassed KCI product portfolio is available in more than 90 countries and delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Committed to advancing the science of healing, KCI sets the standard for leading advanced wound therapy innovation. Headquartered in San Antonio, Texas, Acelity employs nearly 5,000 people around the world.

About Crawford Healthcare

Crawford Healthcare is a rapidly growing international company dedicated to developing innovative treatments and effective dermatological, wound care, and diagnostic products for the care and repair of skin. The Company has worked closely with healthcare professionals for more than 15 years from the international head office of its parent company, Crawford Healthcare Holdings plc (the “Crawford Group”), in Knutsford, Cheshire, U.K. In early 2013, the Crawford Group expanded its operations and opened a United States office in Doylestown, Pa., that focuses on the Company’s portfolio of advanced wound care products.

For more information, contact:

For Acelity:

Kathryn Skeen
Phone: +1 210-882-2067
Email: kathryn.skeen@acelity.com

For Crawford:

John Sullivan
Phone: +44 161 236 1352
Email: johns@thisismc2.com

Crawford Receives New Innovative Technology Contract from Vizient, Inc.

Crawford Receives New Innovative Technology Contract from Vizient, Inc.

[Doylestown, PA. and Cheshire, UK. February 1, 2018]– Crawford Healthcare announced its Touchless Care Zinc Protectant Spray has received an Innovative Technology contract from Vizient, Inc. the largest member driven health care performance improvement company in the country. The contract was based on a recommendation of Touchless Care by hospital experts in this category who serve on one of Vizient’s member-led councils. Vizient reserves its Innovative Technology contracts for technologies that demonstrate an ability to enhance clinical care or patient safety, and those that improve an organization’s care delivery and business model.

 

Touchless Care Zinc Oxide Protectant Spray is a unique product designed to treat incontinence associated dermatitis, commonly referred to as diaper rash. Its formula of 25% Micro-fine Zinc and 20% Dimethicone, coupled with its differentiated application process, helps clinicians and patients by improving clinical outcomes, reducing pain, saving time, supplies and waste. The Micro-fine zinc and Dimethicone mixture allows for better coverage with a breathable, translucent protective barrier that seeps into the cracks and crevasses of the epidermis. The spray-on application allows clinicians to apply the product to sensitive, private and irritated areas without touching the patient. This provides the patient a greater sense of dignity and less pain, while reducing the potential for spreading bacteria through cross contamination.

 

“Crawford Healthcare is excited about the opportunity to work with the Vizient membership and to offer enhanced savings on a product that helps treat a condition that patients and clinicians don’t always want to talk about. This product’s ability to increase patient dignity, reduce pain and help a nurse improve outcomes is prime example of why we are passionate about our company, our jobs and our products. This innovative technology contract demonstrates Crawford’s ability to bring unique and outcomes driven products to the U.S. market,” says Dave Posten, V.P. Sales and U.S. Commercialization.

 

Due to the number of products and services being released and marketed as ‘innovative’, member hospitals truly value the thorough review process in place at Vizient to help them identify products worth further evaluation at their own facilities,”  said Debbie Archer, director of procurement and leader of Vizient’s Innovative Technology program for suppliers. “After a full review of Touchless Care Zinc Protectant Spray, Vizient’s member council agreed this solution offers unique and incremental benefit over other products available on the market today, and recommended it for an Innovative Technology contract. We are pleased to award this new contract to Crawford Healthcare.”

 

Since 2003, nearly 2200 new and innovative products and technologies have been submitted through the Vizient Innovative Technology program. Vizient works with member-led councils and task forces to identify and review potentially innovative products. If it is determined that a product is innovative, a contract may be awarded outside of Vizient’s competitive bid cycle.

 

 

 

About Crawford Healthcare, Inc.

Crawford Healthcare, Inc., is a rapidly growing international company dedicated to developing innovative treatments and effective dermatological, wound care, and diagnostic products for the care and repair of skin. The Company has worked closely with healthcare professionals for more than 15 years from the international head office of its parent company, Crawford Healthcare Holdings Limited (the “Crawford Group”), in Knutsford, Cheshire, U.K. In early 2013, the Crawford Group expanded its operations and opened a United States office in Doylestown, Pa., that focuses on the Company’s portfolio of advanced wound care products.

 

Wonder Dressing Saved my Foot

Wonder Dressing Saved my Foot

FDA cleared KerraCel® Ag dressing uses proprietary technology to combat aggressive, antibiotic-resistant foot ulcers

DOYLESTOWN, Pa. and CHESHIRE, U.K., July 17, 2017 (GLOBE NEWSWIRE) — A 47-year-old Indianapolis, Indiana woman has had her foot saved from amputation just hours before undergoing surgery, thanks to a hi-tech, new ‘wonder dressing’.

 The breakthrough that made the difference for the patient was KerraCel® Ag, a thin, comfortable dressing which is the first FDA-cleared absorbent, gelling wound dressing containing Ag Oxysalts™ – a proprietary silver technology developed and commercialized by Crawford Healthcare and Exciton Technologies. The product, now available to US doctors and their patients, is expert at fighting the powerful and sometimes antibiotic resistant bacteria that diabetic ulcerations and pressure sores can harbor.

Angela Montes de Oca, a 911 police dispatcher for the Marion County Sheriff office in Indianapolis first noticed her foot ulcer towards the end of last year. After the ulcer dramatically worsened, a course of antibiotics proved ineffective and Angela was facing the prospect of amputation.

Admitted to emergency care, Angela was informed the only option was to remove part of her foot, and surgery was scheduled for the following day.

Thanks to an innovative new treatment from Crawford Healthcare, however, Angela avoided amputation and just eight weeks later is now fully recovered.

She said: “Being told I was hours away from amputation was the most terrifying moment of my life, and I say this as someone professionally trained to remain calm. My family, especially my mother, rely on me for care. I have a granddaughter and another one on the way, and I have my two dogs to look after. All I could think about was how caring for them, without my foot, would be impossible. I couldn’t face the prospect of going from being a care-giver to the one in need of care, but every single doctor had told me amputation was my only option.”

Revolutionary Technology

Bringing hope to those facing life-altering surgeries, Crawford Healthcare, a leading international advanced wound care business based in the UK, is offering this breakthrough product in the US called KerraCel® Ag.

KerraCel® Ag is the only wound dressing available that uses silver in its most active state to fight aggressive and antibiotic resistant ulcers and infections from diabetes or pressure sores.

 

In the most serious cases of antiobiotic-resistant diabetic ulcers, amputation has often been considered the

only feasible option, although it is the most devastating. Up to 70 per cent of people die within 5 years after

amputation due to diabetic foot ulceration.* With this new treatment, however, prospects are now significantly brighter for the millions of Americans that face diabetes-related complications each year.

Revolutionary Treatment

This breakthrough provides a unique healing environment that is able to disrupt and kill bacteria within biofilms (bacteria encased in a protective matrix) which show up to 1,000 times resistance to antibiotics and can prevent chronic wounds from healing.

It was recognized wound care expert Dr. Michael S. Miller, Director at The Miller Care Group wound clinic in Indianapolis, that prescribed KerraCel Ag® for Angela.

Dr. Miller said: “I’ve been prescribing KerraCel® Ag to patients with great success, but the severity of Angela’s case demonstrates just how effective this treatment is in promoting healing without any need to consider such drastic alternatives.

“When Angela came to me, it was clear that the priority was to deal with the broad spectrum of bacteria that had managed to get into the wound, which antibiotics were not addressing. KerraCel® Ag is extremely effective in aiding healing and enabling the recovery process to take effect. It’s simple, clean and acts quickly, so it was a no-brainer for me. To achieve such a dramatic turnaround with a patient so close to a life-altering operating is medical innovation at its best.”

After treatment Angela is now able to go about her day with ease and full mobility: “I am incredibly grateful for the treatment Dr. Miller provided and for KerraCel® Ag. I’ll be forever thankful that this incredibly innovative dressing saved my foot.”

 

* Operational Delivery of the Multi-Disciplinary Care Pathway for Diabetic Foot Problems – British Orthopaedic Association

 

About Crawford Healthcare:

Crawford Healthcare is a leading international advanced wound care and dermatology company based in Knutsford, Cheshire England with a US office in Doylstown Pennsylvania. The group develops and sells advanced wound care and dermatology products and is the UK’s fastest-growing advanced wound care company. Crawford Healthcare has a direct sales presence in the UK, USA and Germany.

 

US website: http://crawfordhealthcare.us/

 

About Exciton Technologies:

Exciton Technologies is a commercial stage advanced materials development and manufacturing company, based in Edmonton, Alberta focused on the creation of technologies for preventing and treating infection.

Exciton has developed a portfolio of proprietary and patented processes to incorporate its silver oxysalts (Ag Oxysalts™) technology into a range of products, including Exsalt® SD7 and T7 dressings, to target the advanced wound care and anti-infectives markets.

Crawford Healthcare, Inc. Receives Supplier Horizon Award from Premier Inc.

Crawford Healthcare, Inc. Receives Supplier Horizon Award from Premier Inc.

DOYLESTOWN, Pa., July 11, 2017 (GLOBE NEWSWIRE) — Crawford Healthcare announced that it is a winner of the Supplier Horizon Award from Premier Inc., a leading healthcare improvement company.

One of 11 suppliers to receive the award this year, Crawford Healthcare was recognized for its support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and commitment to lower costs.

“Crawford Healthcare is honored to receive the Horizon Award. The Partnership between Premier and Crawford has enabled thousands of facilities and millions of patients in the US to access to our innovative and life changing products,” says Dave Posten, VP Sales and US Commercialization.

Crawford Healthcare accepted the award at Premier’s 2017 Breakthroughs Conference and Exhibition on June 29.

“Crawford Healthcare supports Premier members by offering valuable products and services that help to lower supply chain costs and improve operating efficiencies,” said Durral R. Gilbert, president of supply chain services, Premier. “We’re honored to recognize them as a Horizon Award recipient.”

Horizon Award winners have tenure of less than three years as a Premier contracted supplier.

About Premier Inc.

Premier Inc. is a leading healthcare improvement company, uniting an alliance of approximately 3,750 U.S. hospitals and more than 130,000 other provider organizations. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Please visit Premier’s news and investor sites on www.premierinc.com .

About Crawford Healthcare, Inc.

Crawford Healthcare, Inc., is a rapidly growing international company dedicated to developing innovative treatments and effective dermatological, wound care, and diagnostic products for the care and repair of skin. The Company has worked closely with healthcare professionals for more than 15 years from the international head office of its parent company, Crawford Healthcare Holdings Limited (the “Crawford Group”), in Knutsford, Cheshire, U.K. In early 2013, the Crawford Group expanded its operations and opened a United States office in Doylestown, Pa., that focuses on the Company’s portfolio of advanced wound care products.

 

Crawford Supports Silver Oxysalts™ Speaker Panel  at the Symposium for Advanced Wound Care

Crawford Supports Silver Oxysalts™ Speaker Panel at the Symposium for Advanced Wound Care

Silver Oxysalts offer a new option in the fight against deadly infections in Chronic Wounds

 

DOYLESTOWN, Pa., April XX, 2017 – Crawford Healthcare, Inc. (“Crawford” or the “Company”) recently supported a panel of speakers at the Symposium for Advanced Wound Care (SAWC) in San Diego, CA. The panel, composed of internationally recognized clinicians and scientists, shared their clinical and in vitro experience in utilizing the patented silver compound, Ag Oxysalts™ Technology, in the fight against wound infections and biofilms.

The symposium was moderated by Dr. Marco Romanelli, a world-renowned wound physician and an Assistant Professor at the University of Pisa in Italy. The panel also included Lindsay Kalan PhD, from the University of Pennsylvania Department of Dermatology, Catherine Milne from Connecticut Clinical Nursing Associates and Dr. Charles Lee, FACS who is the Chief of Plastic Surgery at St. Mary’s Medical Center in San Francisco.

Ag Oxysalts was recently combined into a new dressing and cleared by the FDA. This dressing, named KerraCel® Ag, combines Carboxymethyl Cellulose (CMC) to handle excess exudate with Ag Oxysalts™ to manage infection and break through biofilm. The Ag Oxysalts™ Technology, licensed through Exciton Technologies, has a unique mode of action which makes it significantly more reactive when in contact with wound fluid and up to six times more powerful than traditional silver compounds. The increased reactivity leads to a quick 99.999% kill of bacteria – including superbugs – and the ability to break through biofilm to kill the bacteria within.

For more information about Crawford Healthcare, Inc. or its products, please visit http://crawfordhealthcare.us/

 

About Crawford Healthcare, Inc.

Crawford Healthcare, Inc., is a rapidly growing international company dedicated to developing innovative treatments and effective dermatological, wound care, and diagnostic products for the care and repair of skin. The Company has worked closely with healthcare professionals for more than 15 years from the international head office of its parent company, Crawford Healthcare Holdings Limited (the “Crawford Group”), in Knutsford, Cheshire, U.K. In early 2013, the Crawford Group expanded its operations and opened a United States office in Doylestown, Pa., that focuses on the Company’s portfolio of advanced wound care products. To help lead its U.S. business, the Crawford Group has assembled a skilled management team with long-standing industry backgrounds in the advanced wound care arena. The team offers more than 150 years of collective experience in the field and has deployed a nationwide direct sales team dedicated to wound, skin, and burn care.

About Exciton Technologies, Inc.
Exciton Technologies Inc. (inc. 2001) is a Canadian advanced materials research and development company that focuses on the creation of technologies for preventing and controlling infection. Exciton’s technologies are capable of bringing silver-based wound care products out of the elite market segment and into broader commercial and consumer applications. Advantages include an advanced higher valence ionic silver state designed to be a broad spectrum antimicrobial barrier.

Crawford Healthcare, Inc. awarded Skin Integrity Contract agreement with Premier Inc.

Contract marks the second Premier Contract Award within two years and continued access to thousands of hospitals and healthcare sites.

Contract marks the second Premier Contract Award within two years and continued access to thousands of hospitals and healthcare sites.

 

DOYLESTOWN, Pa., January 26, 2017 – Crawford Healthcare, Inc. (“Crawford” or the “Company”) announced today the signing of a national group purchasing agreement with Premier Inc. (“Premier”), a leading healthcare improvement company.  This three-year award includes both the Primary/Secondary wound care dressings and wound debridement category and the skin cleansers, barrier and lotion products category.  Effective April 1st, these two categories will allow Crawford’s full portfolio of products to be offered at specially negotiated pricing and terms to members of Premier’s alliance, which includes 3,750 hospitals and 130,000 other providers. Premier operates one of the largest healthcare group purchasing organizations (GPOs) in the United States.

Crawford’s innovative line of advanced wound and skin care products was designed with novel technologies to advance the standard of care in the exudate management, infection control and skin protection segments. This national agreement combines Crawford’s products with Premier’s integrated data and analytics, collaboratives, supply chain solutions, advisory and other services to enable better care and outcomes at a lower cost.

“This new contract award is a testament to the clinical acceptance of Crawford’s portfolio and our growth within Premier alliance hospitals over the past year. We look forward to the opportunity to partner with more Premier members who share our values and are striving to overcome the clinical and economic challenges that everyone is facing.” Says Terry Bromley, Senior Vice President and General Manager of Crawford’s U.S. operations

For more information about Crawford Healthcare, Inc. or its products, please visit http://crawfordhealthcare.us/

 

About Crawford Healthcare, Inc.

Crawford Healthcare, Inc., is a rapidly growing international company dedicated to developing innovative treatments and effective dermatological, wound care, and diagnostic products for the care and repair of skin. The Company has worked closely with healthcare professionals for more than 15 years from the international head office of its parent company, Crawford Healthcare Holdings Limited (the “Crawford Group”), in Knutsford, Cheshire, U.K. In early 2013, the Crawford Group expanded its operations and opened a United States office in Doylestown, Pa., that focuses on the Company’s portfolio of advanced wound care products. To help lead its U.S. business, the Crawford Group has assembled a skilled management team with long-standing industry backgrounds in the advanced wound care arena. The team offers more than 150 years of collective experience in the field and has deployed a nationwide direct sales team dedicated to wound, skin, and burn care.

Crawford Receives Recognition for Its Expanded Support of Wound, Ostomy & Continence Nurses Society™

Crawford Receives Recognition for Its Expanded Support of Wound, Ostomy & Continence Nurses Society™

Acknowledgement further validates shared vision of the two organizations.

DOYLESTOWN, Pa., June 22, 2016 – Crawford Healthcare, Inc. (“Crawford” or the “Company”) was recently recognized by the Wound, Ostomy and Continence Nurses Society (WOCN®) with the Silver Supporter Recognition for its support of the Society’s research, advocacy, and programming related to Incontinence Associated Dermatitis (IAD) and other related medical conditions. Crawford’s support of the WOCN Society is largely based upon a common focus in the area of wound, ostomy and continence (WOC)-related ailments. The honor was presented during the WOCN Society and CAET Joint Conference which was held June 4 through 8 in Montreal.

“The WOCN Society is a premiere nursing specialty organization is the world,” says Terry Bromley, Senior Vice President and General Manager of Crawford’s U.S. operations. “Our organizations have shared values and we are proud to stand alongside of them to educate clinicians and improve WOC patient outcomes. Our products support their goals and we are committed to further strengthening this strong partnership moving forward.”

The mission of the WOCN Society is to promote educational, clinical and research opportunities to advance the practice and guide the delivery of expert health care to individuals with wounds, ostomies and incontinence.

Crawford is an international company with global headquarters in the United Kingdom and US operations in Doylestown, Pa.  The company has built a strong reputation for providing innovative products to healthcare professionals and their patients that successfully and cost-effectively treat skin and wound care conditions.

ʺWe are excited about this growing partnership with the team at Crawford,” notes WOCN Society President Carolyn Watts, MSN, RN, CWON. “The Silver Supporter Recognition is well-deserved. They clearly share our goals and support our mission, and we look forward to growing our relationship with them in meaningful ways to continue benefitting patients suffering from WOC-related ailments.”

The largest wound care market in the world is the United States with an estimated $25 billion per year being spent on wound care-related medical costs. These numbers are expected to rise as the number of people in these risk factor categories also continues to rise.  Leading risk factors for developing chronic wounds include diabetes, obesity, and old age.

To learn more about the WOCN Society, visit wocn.org or email info@wocn.org. For more information about Crawford Healthcare, Inc. or its products, please visit us.crawfordhealthcare.com.

About the WOCN® Society
Founded in 1968, the Wound, Ostomy and Continence Nurses Society™ is a professional, international nursing society of over 5,000 health care professionals who are experts in the care of patients with wounds, ostomies and incontinence. The Society supports its members by promoting educational, clinical and research opportunities to advance the practice and guide the delivery of healthcare to individuals with wounds, ostomies and incontinence. Connect with the WOCN Society on Facebook at Wound, Ostomy and Continence Nurses Society (WOCN), on Twitter at @WOCN Society, and on LinkedIn at Wound, Ostomy and Continence Nurses Society™.

About Crawford Healthcare, Inc.
Crawford Healthcare, Inc., is a rapidly growing international company dedicated to developing innovative treatments and effective dermatological, wound care, and diagnostic products for the care and repair of skin. The Company has worked closely with healthcare professionals for more than 15 years from the international head office of its parent company, Crawford Healthcare Holdings Limited (the “Crawford Group”), in Knutsford, Cheshire, U.K. In early 2013, the Crawford Group expanded its operations and opened a United States office in Doylestown, Pa., that focuses on the Company’s portfolio of advanced wound care products. To help lead its U.S. business, the Crawford Group has assembled a skilled management team with long-standing industry backgrounds in the advanced wound care arena. The team offers more than 150 years of collective experience in the field and has deployed a nationwide direct sales team dedicated to wound, skin, and burn care.

Crawford Supports Incontinence-Associated Dermatitis Symposium

Crawford Supports Incontinence-Associated Dermatitis Symposium

DOYLESTOWN, Pa., June 14, 2016 – Crawford Healthcare, Inc. (“Crawford” or the “Company”) recently supported a distinguished group of clinicians for a symposium at the WOCN® Society and CAET Joint Conference. The panel shared their insight and clinical experience in utilizing a novel, touch-free, micro-fine zinc oxide technology to help increase patient comfort, compliance among staff, and treat Incontinence Associated Dermatitis (IAD).

Touchless Care® Zinc Oxide Protectant Spray offers protection and soothing relief for continence conditions and chronic wound care.

Traditionally, IAD has received little attention as a distinct disorder and it is sometimes confused with stage I or II pressure ulcers. Prevention is based on avoiding or minimizing exposure to stool or urine combined with a structured skincare program based on principles of gentle cleansing, moisturization (preferably with an emollient), and application of a skin protectant.  If not properly treated, IAD can lead to pressure ulcers and extended, costly hospital stays.

Crawford’s Touchless Care® Zinc Oxide Protectant Spray is an innovative advanced skin care product for the management and treatment of IAD. The spray-on product utilizes a novel technology designed to advance the standard of skin care in all care settings. The product soothes, protects, and treats irritated skin with 25% Zinc Oxide and 20% Dimethicone without the mess and pain associated with traditional rubbed-in ointments and pastes. The touchless spray application is designed to reduce contact with incontinent patients helping to reduce the chances of cross-contamination between patients and caregivers.

“We are very pleased to support the WOCN conference and this presentation on IAD,” notes Terry Bromley, Senior Vice President and General Manager of Crawford’s U.S. operations. “Our Touchless Care Zinc Oxide Protectant Spray is a natural fit for this discussion on this very challenging condition. Further, working with the WOCN and this highly qualified group of panelists has truly been a rewarding experience for our company.”

The Wound, Ostomy and Continence Nurses Society™ is recognized worldwide for the promotion of safe and effective wound, ostomy and continence (WOC) care. Leading healthcare organizations acknowledge that the Society is the premiere nursing specialty organization to educate clinicians and improve WOC patient outcomes. To learn more, visit wocn.org or email info@wocn.org. For more information about Crawford Healthcare, Inc. or its products, please visit us.crawfordhealthcare.com.

About the WOCN® Society
Founded in 1968, the Wound, Ostomy and Continence Nurses Society™ is a professional, international nursing society of over 5,000 health care professionals who are experts in the care of patients with wounds, ostomies and incontinence. The Society supports its members by promoting educational, clinical and research opportunities to advance the practice and guide the delivery of healthcare to individuals with wounds, ostomies and incontinence. Learn more by visiting wocn.org. Connect with the WOCN Society on Facebook at Wound, Ostomy and Continence Nurses Society (WOCN), on Twitter at @WOCNSociety, and on LinkedIn at Wound, Ostomy and Continence Nurses Society™.

About Crawford Healthcare, Inc.
Crawford Healthcare, Inc., is a rapidly growing international company dedicated to developing innovative treatments and effective dermatological, wound care, and diagnostic products for the care and repair of skin. The Company has worked closely with healthcare professionals for more than 15 years from the international head office of its parent company, Crawford Healthcare Holdings Limited (the “Crawford Group”), in Knutsford, Cheshire, U.K. In early 2013, the Crawford Group expanded its operations and opened a United States office in Doylestown, Pa., that focuses on the Company’s portfolio of advanced wound care products. To help lead its U.S. business, the Crawford Group has assembled a skilled management team with long-standing industry backgrounds in the advanced wound care arena. The team offers more than 150 years of collective experience in the field and has deployed a nationwide direct sales team dedicated to wound, skin, and burn care.

Crawford Healthcare Gives Back

Crawford Healthcare Gives Back

In keeping with our commitment to support the local communities where we work, Crawford Healthcare held a team building event during it’s National Training meeting in Coral Gables, Florida to benefit the Golisano Children’s Hospital of Southwest Florida.

The event, designed to foster teamwork and inspire the attendees to give back, raised more than $2,000 and donated 75 toys to the children and their siblings who spend extended time at the hospital due to illness and trauma.  Crawford would like to thank the Nurses and Therapists for attending the event and sharing the hospital’s mission and the children’s stories.

Above, one of the four teams shows off their make-believe toy store that was created with craft supplied and toys, then judged by the clinicians from Colisano Children’s Hospital of Southwest Florida.

Crawford Healthcare, Inc. Awarded Group Purchasing Contract with Premier, Inc.

This national agreement gives Premier members a new partner to help tackle costly challenges such as hospital-acquired pressure ulcers, wound infection, increased length of stay, and hospital readmissions.

DOYLESTOWN, Pa., April 11, 2016 – Crawford Healthcare, Inc. (“Crawford” or the “Company”) announced today the signing of a national group purchasing agreement with Premier, Inc. (“Premier”), a leading healthcare improvement company, to offer Crawford’s full line of products at specially negotiated pricing and terms. Premier unites an alliance of 3,600 hospitals and 120,000 other providers, and operates one of the largest healthcare group purchasing organizations (GPOs) in the United States.

Crawford’s innovative line of advanced wound and skin care products was designed with novel technologies to advance the standard of care in the exudate management, infection and protection segments. This national agreement gives Premier members a new partner to help tackle costly challenges such as hospital-acquired pressure ulcers, wound infection, increased length of stay, and hospital readmissions.

“We are very pleased to have been chosen for this contract based on our shared values of supporting outstanding clinical and economic outcomes,” says Terry Bromley, Senior Vice President and General Manager of Crawford’s U.S. operations. “Premier is widely recognized for having the highest ethical standards, and for its commitment to improving healthcare quality, access and affordability,” adds Bromley. “Crawford is proud to be working with such a partner.”

Among the products included in the contract with Premier are Crawford’s proven performers: KerraMax Care™, a super-absorbent dressing designed to minimize discomfort and dressing changes; KerraFoam™, a foam dressing with excellent fluid retention capabilities to prevent maceration and wound edge breakdown; KerraContact™ Ag, a contact layer containing proprietary Ag Oxysalts™ for fast and powerful antimicrobial action; and Touchless® Care, a spray-on, no-rub-in series of multipurpose treatments that soothe and protect irritated skin.

For more information about Crawford Healthcare, Inc. or its products, please visit us.crawfordhealthcare.com.

About Crawford Healthcare, Inc.
Crawford Healthcare, Inc., is a rapidly growing international company dedicated to developing innovative treatments and effective dermatological, wound care, and diagnostic products for the care and repair of skin. The Company has worked closely with healthcare professionals for more than 15 years from the international head office of its parent company, Crawford Healthcare Holdings Limited (the “Crawford Group”), in Knutsford, Cheshire, U.K. In early 2013, the Crawford Group expanded its operations and opened a United States office in Doylestown, Pa., that focuses on the Company’s portfolio of advanced wound care products. To help lead its U.S. business, the Crawford Group has assembled a skilled management team with long-standing industry backgrounds in the advanced wound care arena. The team offers more than 150 years of collective experience in the field and has deployed a nationwide direct sales team dedicated to wound, skin, and burn care.